
The FDA announced in August that it has expanded the indication for Merck's approved hepatitis A vaccine (Vaqta) to include patients 12 months and older. Previously, Vaqta was approved for children 2 years and older. The change is the result of an open-label study of children with no evidence of hepatitis A infection.